Dec 21 (Reuters) - Pharming Group NV PHAR.AS :
* Pharming and Hyupjin announce receipt of the South Korean
marketing authorization for Ruconest
* Ruconest is approved for treatment of acute angioedema
attacks in adult patients with hereditary angioedema HAE
* Says its South-Korean partner Hyupjin will now seek
reimbursement for Ruconest in South Korea
Source text for Eikon: ID:nPre7z6zta
Further company coverage: PHAR.AS
(Gdynia Newsroom:)